A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: DVT

  • Apixaban (Eliquis®) – Another New Oral Anticoagulant

    Good news.  Another one of the new oral anticoagulants in development,  Apixaban (Eliquis®), has moved forward.  On May 20th, 2011, the European Medicines Agency (EMA) approved Eliquis® for DVT prevention after orthopedic surgery (hip and knee replacement) in the 27 countries of the European Community. In the U.S., however, Eliquis® is still some way away from getting FDA approval

  • Apixaban (Eliquis): Another New Oral “Blood Thinner”

    Good news. Another one of the new oral “blood thinners” in development,  Apixaban (Eliquis®), has moved forward. On May 23rd, 2011 the European Medicines Agency (EMA) approved Eliquis® for marketing in the 27 countries of the European Community for DVT prevention after orthopedic surgery (hip and knee replacement). In the U.S., Eliquis® is not yet FDA approved, and still…

  • What Causes Clots? – A Family Study

    Background It is known that the risk for blood clots in the leg (DVT) and lung (PE) is partly inherited. Some genes that increase the risk for DVT and PE are known (e.g. factor V Leiden, the factor II 20210 mutation, protein, protein C, S and antithrombin mutations). However, it is suspected that many other and,…

  • Athletes and DVT + PE

    Background Many people think of DVT and PE as a problem occurring in elderly people, but not in young and apparently healthy individuals. While it is certainly true that they occur more commonly in the elderly and in non-athletic overweight individuals, they can, nevertheless, happen in young, normal weight, and athletic people.

  • Athletes and Blood Clots

    Many people think of blood clots as a problem occurring in elderly people, but not in young and apparently healthy individuals. While it is true that clots occur more commonly in the elderly and in non-athletic overweight individuals, they can, nevertheless, happen in young, normal weight, and athletic people.

  • Acute Proximal DVT – Offering Patients Enrollment into ATTRACT Trial

    If you as a health care professional are involved in the management of patients with acute (proximal) DVT, please consider giving the patient (who has leg symptoms ≤ 14 days) an opportunity to be enrolled in the national ATTRACT trial (information on the trial is here). This NIH-funded, multi-center trial investigates whether catheter-directed thrombectomy (±…

  • HIT = Heparin-induced Thrombocytopenia

    What Is HIT? Heparin-induced thrombocytopenia (HIT) is a serious side effect that may occur when you are being treated with heparin. It may lead to low blood platelet counts and to life-threatening blood clots.

  • Symptoms of DVT and PE

    DVT (Deep Vein Thrombosis) A DVT is a blood clot that most commonly occurs in the leg, typically only one leg (image 1). However, occasionally it occurs in both legs at the same time (=bilateral DVT). Sometimes, a DVT is in the pelvic veins or the big abdominal vein (=inferior vena cava). And some DVTs…